However, these agents significantly benefit only about 40–60% of migraine patients, suggesting the involvement of additional factors beyond CGRP in migraine pathophysiology.37 A phase 2 trial for Lu AG09222, the first PACAP-targeting monoclonal antibody directed against the PACAP ligand, highlights its potential as a novel preventive treatment for migraine. Here, ADCYAP1 is linked to migraine disorder.